title: [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
abstract: We conducted a clinical study of MTX-HOPE (day 1, methotrexate 20 mg per os (po); day 2, hydrocortisone 100 mg intravenous (iv), vincristine 1 mg iv; day 3,4 sobuzoxane 400 mg po; etoposide 25 mg po, repeating every 2 or 3 weeks) in 14 relapsed or refractory patients with non-Hodgkin's lymphoma. Ten responders were obtained 5 CR and 5 PR), and heavily treated patients were included in the responders. The median duration of over all survival which was estimated with Kaplan-Meier curve was 11.1 months (range, 2-18+ months), and the median duration of response was 6.9 months (range, 0.8+ -16.4+ months). Out of the 14 patients,eleven were treated with this regimen in an outpatient setting. Grade 4 neutropenia and thrombocytopenia were observed in 4 and 2 patients,and grade 3 GPT-elevation and stomatitis in two and one, respectively. This newly developed MTX-HOPE therapy may be a promising treatment option for such patients as are intolerable for high-dose chemotherapies with PBSC rescue or wish for outpatient therapy.
authors.affiliation: Division of Hematology, Tochigi Cancer Center.
authors.forename: Saburo
authors.initials: S
authors.lastname: Tsunoda
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Koichi
authors.initials: K
authors.lastname: Inoue
authors.forename: Tohru
authors.initials: T
authors.lastname: Izumi
authors.forename: Miyuki
authors.initials: M
authors.lastname: Akutsu
authors.forename: Susumu
authors.initials: S
authors.lastname: Katano
authors.forename: Tomoki
authors.initials: T
authors.lastname: Ueda
authors.forename: Toshitaka
authors.initials: T
authors.lastname: Shirai
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Masuda
authors.forename: Kenichi
authors.initials: K
authors.lastname: Ohmine
authors.forename: Takahiro
authors.initials: T
authors.lastname: Nagashima
authors.forename: Masuzu
authors.initials: M
authors.lastname: Ueda
authors.forename: Syojiro
authors.initials: S
authors.lastname: Takagi
authors.forename: Kazuo
authors.initials: K
authors.lastname: Muroi
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Kano
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000401:mortality; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010879:Piperazines / Q000008:administration & dosage; D016879:Salvage Therapy; D015996:Survival Rate; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D010879:Piperazines; D014750:Vincristine; D005047:Etoposide; C057773:sobuzoxane; D006854:Hydrocortisone; D008727:Methotrexate